<DOC>
	<DOCNO>NCT00949910</DOCNO>
	<brief_summary>This study provide treatment erlotinib participant advance NSCLC receive least one course standard chemotherapy radiation therapy , medically suitable either . Efficacy safety monitor throughout study .</brief_summary>
	<brief_title>An Expanded Access Program Tarceva ( Erlotinib ) Participants With Advanced Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Adults great equal ( â‰¥ ) 18 year age Histologically cytologically document inoperable , locally advanced , metastatic , recurrent NSCLC Previous treatment 2 prior chemotherapy regimens Previous systemic anticancer therapy human epidermal growth factor receptor 1 ( HER1 ) /epidermal growth factor receptor ( EGFR ) inhibitors Inability take oral medication Any malignancy within 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>